Skip to search formSkip to main contentSkip to account menu

rituximab

Known as: AntiCD20, Ig gamma-1 chain C region, Rituximab CD20 Antibody 
A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and… 
National Institutes of Health

Related topics

Related topics

40 relations
10 ML rituximab 10 MG/ML Injection [Rituxan]50 ML rituximab 10 MG/ML InjectionB-Cell LymphomasCytotoxic T-Lymphocytes

Broader (4)

Antineoplastic AgentsAntirheumatic AgentsImmunologic FactorsMonoclonal Antibodies

Narrower (5)

IDEC-C2B8 AntibodyMabtheraRituxanRituximab Biosimilar PF-05280586

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Anti-CD20 Therapy Acts via Fc g RIIIA to Diminish Responsiveness of Human Natural Killer Cells
Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggregating Fc g RIIIA/CD16… 
Review
2012
Review
2012
Can next-generation antibodies offset biosimilar competition?
With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D… 
2009
2009
Increased intestinal permeability in deceased brain dead rats.
2007
2007
Rituximab : effective treatment for severe steroid-dependent minimal change nephrotic syndrome ?
Sir, Minimal change disease (MCNS) accounts for 70–90% of the cases of idiopathic nephrotic syndrome in children. Most patients… 
Highly Cited
2006
Highly Cited
2006
Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab… 
Highly Cited
2004
Highly Cited
2004
Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.
To address early and late treatment failures in DLBCL in patients age 60 and greater, we performed a prospective 2 x 2 randomized… 
2002
2002
A Clinicopathologic and Immunohistochemical Study of Seven Patients
1999
1999
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
We evaluated the response and toxicity of rituximab in the setting of progressive intermediate grade non-Hodgkin’s lymphoma (NHL… 
1998
1998
Micronucleus frequencies in cytokinesis-blocked human B lymphocytes after low dose gamma-irradiation.
PURPOSE To investigate (1) the radiosensitivity of B versus T lymphocytes with respect to micronucleus (MN) induction and (2) the… 
Highly Cited
1996
Highly Cited
1996
Anti‐dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)
The objective was to serially analyse T and B cell activation in relation to autoantibody production during the development of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)